QIAGEN said it was awarded a contract from the U.S. government to increase the production capacity for COVID-19 testing consumables used on its NeuMoDx 96 and 288 integrated PCR testing systems.
Specifically, the Department of Defense (DOD), coordinating with Department of Health and Human Services (HHS), awarded a $3.4 million contract to QIAGEN to expand production capacity at its site in Ann Arbor, MI.
By the end of March 2022, QIAGEN plans to scale up production to more than 16 million tests per year, up from the current level of about 10 million.
This contract follows a DOD announcement in August 2021 that it and HHS had awarded QIAGEN a contract for approximately $600,000 to expand production capacity for chemical reagents. The QIAGEN site at Beverly, MA, is the center of the company’s reagent manufacturing for other Original Equipment Makers (OEMs) in the molecular testing market, including for COVID-19 tests.
